Explore

Rapid Read Rapid Read
AI Integration in IDF Mental Health Care Aims to Improve Trauma Treatment for Soldiers

AI Integration in IDF Mental Health Care Aims to Improve Trauma Treatment for Soldiers

The Israeli Defense Forces (IDF) and the Defense Ministry are implementing artificial intelligence (AI) to enhance mental health care for soldiers suffering from post-traumatic stress disorder (PTSD) and other emotional traumas. This initiative is part of a broader effort to overhaul the treatment of nearly 50,000 former soldiers affected by emotional trauma. The government committee, led by Prof. Shlomo Mor-Yosef, has recommended significant changes, including the establishment of an independent authority to manage these cases more efficiently. The committee's report highlights the need for increased funding and resources, suggesting a budget increase from NIS 5 billion to NIS 10 billion, with an additional NIS 2 billion annually. AI is being used to streamline processes, reduce record-keeping time for professionals, and provide personalized 'calming cues' through EEG machines. This approach aims to expedite treatment and improve the quality of care for affected soldiers.
Rapid Read Rapid Read
SERENA-6 Trial Explores New Treatment for Endocrine Resistance in Metastatic Breast Cancer

SERENA-6 Trial Explores New Treatment for Endocrine Resistance in Metastatic Breast Cancer

The SERENA-6 trial, a randomized, double-blind, placebo-controlled study, is investigating the efficacy of camizestrant in patients with hormone receptor-positive metastatic breast cancer (HR+ mBC) who develop ESR1 mutations (ESR1m) during first-line treatment with aromatase inhibitors (AI) and CDK4/6 inhibitors. The trial aims to determine if switching to camizestrant, an oral selective estrogen receptor degrader (SERD), can extend progression-free survival (PFS) compared to continuing the standard AI and CDK4/6i therapy. The study's design is notable for its use of circulating tumor DNA (ctDNA) to guide treatment decisions, allowing for a personalized approach to therapy. Initial results suggest that camizestrant may offer clinical benefits by targeting ESR1m, a common mechanism of resistance in HR+ mBC.
Trendline Trendline
Tempus to Present AI-Driven Precision Medicine Insights at Goldman Sachs Healthcare Conference

Tempus to Present AI-Driven Precision Medicine Insights at Goldman Sachs Healthcare Conference

Tempus to Present AI-Driven Precision Medicine Insights at Goldman Sachs Healthcare Conference
Trendline Trendline
Tempus to Present AI-Driven Precision Medicine at Goldman Sachs Healthcare Conference

Tempus to Present AI-Driven Precision Medicine at Goldman Sachs Healthcare Conference

Tempus to Present AI-Driven Precision Medicine at Goldman Sachs Healthcare Conference
Rapid Read Rapid Read
Memorial Sloan Kettering Cancer Center's Immunotherapy Breakthrough Offers New Hope for Colorectal Cancer Patients

Memorial Sloan Kettering Cancer Center's Immunotherapy Breakthrough Offers New Hope for Colorectal Cancer Patients

Recent clinical research conducted by Memorial Sloan Kettering Cancer Center has revealed a significant breakthrough in the treatment of colorectal cancer. The study highlights the potential of immunotherapy, specifically PD-1 inhibitors, to achieve complete tumor remission in certain colorectal cancers characterized by deficient mismatch repair (dMMR) or high microsatellite instability (MSI-H). This development is particularly noteworthy as it suggests that some patients with locally advanced rectal cancer could experience full clinical responses without the need for chemotherapy, radiation, or surgery. The implications of this research are profound, as traditional surgical treatments for rectal cancer often result in life-altering consequences, such as colostomies and long-term bowel dysfunction. If these findings are confirmed in larger trials, immunotherapy could become a new standard of care for select patients, offering a less invasive and more personalized treatment option.
Rapid Read Rapid Read
Breakthrough in Colorectal Cancer Treatment with Immunotherapy

Breakthrough in Colorectal Cancer Treatment with Immunotherapy

Researchers have announced a significant breakthrough in colorectal cancer treatment, revealing that certain tumors can be eradicated using immunotherapy alone, without the need for chemotherapy or surgery. This development, highlighted by Memorial Sloan Kettering Cancer Center, focuses on colorectal cancers with deficient mismatch repair (dMMR) or high microsatellite instability (MSI-H). Early clinical trials have shown complete tumor remission in some patients, suggesting a potential shift towards less invasive treatment options. This approach could reduce the need for surgeries, which often result in life-altering consequences such as colostomies and long-term bowel dysfunction.
Trendline Trendline
Mevion Medical Systems Introduces Compact Proton Therapy at Stanford Medicine

Mevion Medical Systems Introduces Compact Proton Therapy at Stanford Medicine

Mevion Medical Systems Introduces Compact Proton Therapy at Stanford Medicine
Rapid Read Rapid Read
Research Highlights Gut Microbiome's Role in Cancer Treatment

Research Highlights Gut Microbiome's Role in Cancer Treatment

Recent research has highlighted the potential role of the gut microbiome in enhancing cancer treatment outcomes. Studies suggest that a healthier gut microbiome may improve the effectiveness of immunotherapy in cancer patients. Researchers are exploring various interventions, including probiotics and dietary changes, to manipulate the gut microbiome and boost immune responses against cancer. This emerging field of study is gaining attention for its potential to revolutionize cancer care by leveraging the body's natural microbiota.
Rapid Read Rapid Read
Osara Health Expands Cancer Support with New Survivorship Care Modules

Osara Health Expands Cancer Support with New Survivorship Care Modules

Osara Health, a digital health company, has announced the expansion of its Cancer Coach program to include new survivorship modules. These modules are designed to support individuals living beyond active cancer treatment, addressing the ongoing physical, emotional, and practical challenges they face. The expansion is based on findings that nearly 54% of cancer survivors experience fear of recurrence and 25% face psychosocial distress. The new modules offer personalized support through human coaching and digital tools, aiming to improve participants' physical and mental health.
Rapid Read Rapid Read
Healthcare Organizations Urged to Adopt AI for Enhanced Cybersecurity

Healthcare Organizations Urged to Adopt AI for Enhanced Cybersecurity

At the Infosecurity Europe conference, experts highlighted the urgent need for healthcare organizations (HCOs) to adopt AI-powered tools to better detect and contain cybersecurity threats. Sher Baig, CEO of Cyber Salus, emphasized that legacy infrastructure and human fatigue are creating significant risks, with ransomware posing a particular threat to clinical services. According to Proofpoint research, 93% of HCOs experienced at least one cyber-attack in 2025, with an average of 43 attacks per organization. The conference underscored the importance of transitioning from reactive to proactive security measures, utilizing AI for continuous monitoring and faster anomaly detection.
Rapid Read Rapid Read
Mevion Medical Systems Completes First Clinical Treatment with MEVION S250-FIT Proton Therapy System at Stanford

Mevion Medical Systems Completes First Clinical Treatment with MEVION S250-FIT Proton Therapy System at Stanford

Mevion Medical Systems has announced the successful completion of the first clinical treatment using its MEVION S250-FIT Proton Therapy System at Stanford Medicine Cancer Center. This marks a significant milestone as it is the first time a proton therapy treatment has been delivered inside an existing conventional radiation therapy vault. The MEVION S250-FIT system is a compact, single-room proton therapy solution that integrates seamlessly into existing radiation oncology infrastructure, eliminating the need for constructing dedicated proton therapy bunkers. This innovation allows for high-quality CT image guidance directly at the treatment position, addressing space constraints and facilitating the integration of advanced particle therapy into existing oncology programs.
USA Today USA Today
A triple negative breast cancer diagnosis, and the queer affirmation that kept her going

A triple negative breast cancer diagnosis, and the queer affirmation that kept her going

An integral part to Alix Shulman's medical care was her support system, from medical providers to loved ones, affirming her queer identity and recognizing her spouse.